Fig. 5.

Gemcitabine decreases MDSCs that persist in the lungs after primary tumor resection and subsequent 4T1 growth in the lungs. a Experimental outline for (b–d); lung tissues were harvested as indicated from mice with or without 4T1 tumor resection and/or 60 mg/kg gemcitabine treatment for flow cytometry-based assessment of lung leukocytes. b Number of granulocytic-MDSCs or monocytic-MDSCs in the lungs of mice treated as in (a). Data are mean ± SEM of 7–8 mice per group. Significance compared to naïve (tumor-free) mice. c Number of macrophages in the lungs of mice treated as in (a). Data are mean ± SEM of 3–5 mice per group. d Number of eosinophils in the lungs of mice treated as in (a). Data are mean ± SEM of 3–5 mice per group. e Experimental outline for (f); lung tissues were harvested as indicated from mice with 4T1 tumor resection, gemcitabine treatment, and/or iv injection of 4T1 tumor cells prior to quantification of 4T1 cells in the lungs. f Total number of 4T1 tumor cells in the lungs of mice from (e). Data are mean ± SEM of 7–8 mice per group